Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Xilio Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 35 | 35 | 0 |
| Shares | 25.9M | 22.5M | −3.33M (−12.9%) |
| Value | $24.7M | $16.3M | −$8.37M (−33.9%) |
New holders (6)
Institutions that held Xilio Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Avantax Planning Partners, Inc. | 150,399 | $108.9K | 0.00% |
| Millennium Management LLC | 51,110 | $37.0K | 0.00% |
| Scientech Research LLC | 42,546 | $30.8K | 0.01% |
| ADAR1 Capital Management, LLC | 40,000 | $29.0K | 0.01% |
| Dunhill Financial, LLC | 10,274 | $7.44K | 0.00% |
| Investors Asset Management of Georgia Inc | 10,000 | $7.24K | 0.00% |
Sold out (6)
Institutions that held Xilio Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Rock Springs Capital Management LP | 3,003,259 | $2.87M |
| FIL Ltd | 218,705 | $208.9K |
| Susquehanna International Group, LLP | 49,093 | $46.9K |
| Citadel Advisors LLC | 40,316 | $38.5K |
| XTX Topco Ltd | 12,870 | $12.3K |
| Tower Research Capital LLC (TRC) | 2,729 | $2.61K |